Evidence map›Paper›PMID 35861705›Full record

ArticlePathogens and global health2023

Evaluation of the antileishmanial effect of polyclonal antibodies and cationic antimicrobial peptides.

Mahsa Esmaeilifallah, Hossein Khanahmad, Zahra Ghayour, Sedighe Saberi, Reza Kalantari, Seyed Hossein Hejazi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens and global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mahsa EsmaeilifallahDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0001-9125-920X
Hossein KhanahmadDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-5573-3557
Zahra GhayourDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-7490-6767
Sedighe SaberiDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0003-2217-8945
Reza KalantariDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0001-9118-3014
Seyed Hossein HejaziSkin Diseases and Leishmaniasis Research Centre, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-3733-1220
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is one of the tropical and subtropical diseases which, according to WHO, has the priority of control. The list of anti-leishmanial drugs is limited and requires side effects, high costs, and long-term treatments. Various species, parasite resistance, and simultaneous diseases are among the factors that affect the effectiveness of treatment. Due to these problems and based on satisfactory records of previous studies using antimicrobial peptides (AMPs) against infectious diseases, this study aimed to evaluate the antileishmanial effect of

Indexed as

Antiprotozoal AgentsLeishmania majorLeishmaniasisAnimalsAntimicrobial Cationic PeptidesMacrophagesMiceMice, Inbred BALB CAntimicrobial Cationic PeptidesAntiprotozoal AgentsAMPanimal modelcationic antimicrobial peptidesLeishmaniapolyclonal antibodies

Identifiers

PMID35861705
PMCPMC10177747
OpenAlexW4286498700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.